Patent ID: 11969404
Assignee: AXSOME MALTA LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a human subject with [R]-2-amino-3-phenylpropylcarbamate (APC) in need thereof having a history of bipolar disorders, said method comprising:
determining if the patient has moderate or severe renal impairment based on the estimated glomerular filtration rate (eGFR) of the subject, and
(a) providing to a subject having an estimated glomerular filtration rate (eGFR) of about 30 mL/min/1.73 m2 to about 59 mL/min/1.73 m2:
a first oral daily dose equivalent to 37.5 mg APC from day one to day n1 of a dose escalation regimen, and
a second oral daily dose equivalent to 75 mg APC starting on day n2 of the dose escalation regimen,, wherein n1 is an integer equal to or greater than 5 and n2 is equal to the sum of n1+1,, wherein the subject is not provided a daily dose exceeding a dose equivalent to 75 mg APC; and
(b) providing to a subject having an eGFR of about 15 mL/min/1.73 m2 to about 29 mL/min/1.73 m2:
an oral daily dose equivalent to 37.5 mg APC,, wherein the subject is not provided a daily dose exceeding a dose equivalent to 37.5 mg APC.